alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 79, Number 246 (Tuesday, December 23, 2014)]
[Notices]
[Pages 77038-77039]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-30029]


-----------------------------------------------------------------------

NATIONAL ARCHIVES AND RECORDS ADMINISTRATION

Office of Government Information Services (OGIS)

[NARA-2015-017]


Freedom of Information Act (FOIA) Advisory Committee; Meeting

AGENCY: National Archives and Records Administration (NARA).

ACTION: Notice of FOIA Advisory Committee Meeting,

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act (5 
U.S.C. App) and the second United States Open Government National 
Action Plan (NAP) released on December 5, 2013, NARA announces an 
upcoming Freedom of Information Act (FOIA) Advisory Committee meeting.

DATES: The meeting will be on January 27, 2015, from 10:00 a.m. to 1:00 
p.m. EST. Registration for the meeting must be completed on or before 
5:00 p.m. EST January 26, 2015.

ADDRESSES: National Archives and Records Administration (NARA); 700 
Pennsylvania Avenue NW; Archivist's Reception Room (Room 105); 
Washington, DC 20408.

FOR FURTHER INFORMATION CONTACT: Christa Lemelin, Designated Federal 
Officer for this committee, by mail at National Archives and Records 
Administration; Office of Government Information Services; 8601 Adelphi 
Road--OGIS; College Park, MD 20740-6001, by telephone at 202-741-5773, 
or by email at <a href="/cdn-cgi/l/email-protection#13507b617a6067723d5f767e767f7a7d537d7261723d747c65"><span class="__cf_email__" data-cfemail="e4a78c968d979085caa8818981888d8aa48a859685ca838b92">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The purpose of this meeting is to discuss 
the FOIA issues on which the Committee is focusing its efforts: 
oversight and accountability, proactive disclosures, and fees. This 
meeting will be open to the public. However, due to space limitations 
and access procedures, NARA requests that individuals planning to 
attend register for the event via Eventbrite at http://www.eventbrite.com/e/freedom-of-information-act-foia-advisory-committee-meeting-registration-14028440443. Eventbrite registration for 
the meeting will go live on Tuesday, January 6, 2015, at 10:00 a.m. 
EST. Members of the media who wish to register, those who are unable to 
register

[[Page 77039]]

via Eventbrite, and those who require special accommodations, should 
contact Christa Lemelin at the contact information listed above. The 
FOIA Advisory Committee Web page at https://ogis.archives.gov/foia-advisory-committee/meetings.htm contains an agenda and additional 
instructions for participation.

    Dated: December 17, 2014,
Patrice Little Murray,
Committee Management Officer.
[FR Doc. 2014-30029 Filed 12-22-14; 8:45 am]
BILLING CODE 7515-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
I 

118TH CONGRESS 

1ST SESSION H. R. 2104 

To provide for a limitation on availability of funds for District of Columbia, 

Federal Payment for Testing and Treatment of HIV/AIDS for fiscal 

year 2024. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 29, 2023 

Mr. BIGGS (for himself, Mr. ROSENDALE, Mr. GAETZ, Mr. GOOD of Virginia, 

Mr. ROY, and Mr. CRANE) introduced the following bill; which was referred to the Committee on Oversight and Accountability 

A BILL 

To provide for a limitation on availability of funds for District of Columbia, Federal Payment for Testing and 

Treatment of HIV/AIDS for fiscal year 2024. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. LIMITATION ON AVAILABILITY OF FUNDS FOR 

4 DISTRICT OF COLUMBIA, FEDERAL PAYMENT 

5 FOR TESTING AND TREATMENT OF HIV/AIDS 

6 FOR FISCAL YEAR 2024. 

7 Notwithstanding any other provision of the law, 

8 amounts authorized to be appropriated or otherwise avail9 able for District of Columbia, Federal Payment for TestVerDate Sep 11 2014 06:09 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H2104.IH H2104

DMWilson on DSKJM0X7X2PROD with BILLS
2 

•HR 2104 IH

1 and Treatment of HIV/AIDS for fiscal year 2024 may not 

2 exceed $3,000,000. 

Æ 


DMWilson on DSKJM0X7X2PROD with BILLS
#### The People of the State of New York, Respondent, v Cesar Montalvo, Appellant.

[961 NYS2d 324]

*775Appeal by the defendant from a judgment of the Supreme Court, Queens County (Blumenfeld, J.), rendered July 20, 2010, convicting him of burglary in the second degree, upon his plea of guilty, and imposing sentence.

Ordered that the judgment is affirmed.

The defendant moved to withdraw his plea of guilty on the ground that the plea was not knowing, voluntary, and intelligent because, inter alia, his attorney allegedly rendered ineffective assistance. After a hearing, the defendants’ motions were denied.

Contrary to the defendant’s contention, his waiver of the right to appeal was knowing, voluntary, and intelligent *(see People v Lopez,*6 NY3d 248, 256 [2006]; *People v Seaberg,*74 NY2d 1, 11 [1989]). Because the defendant voluntarily waived his right to appeal, his claim that he was deprived of his right to effective assistance of counsel is precluded, except to the extent that the alleged ineffective assistance may have affected the voluntariness of his plea *(see People v Ramos,*77 AD3d 773, 774 [2010]; *People v Drago,*50 AD3d 920, 920 [2008]; *People v Demosthene,*2 AD3d 874, 874 [2003]). Insofar as he contends that his counsel’s conduct affected the voluntariness of his plea, contrary to the defendant’s contention, his attorney provided him with meaningful representation *(see People v Caban,*5 NY3d 143, 152 [2005]; *People v Baldi,*54 NY2d 137, 147 [1981]). Moreover, the record demonstrates that the defendant’s plea of guilty was knowingly, voluntarily, and intelligently entered *(see People v Fiumefreddo,*82 NY2d 536, 543 [1993]; *People v Lopez,*71 NY2d 662, 666 [1988]; *People v Harris,*61 NY2d 9, 16 [1983]). Accordingly, the Supreme Court providently exercised its discretion in denying the defendant’s motions to withdraw his guilty plea *(see generally People v Seeber,*4 NY3d 780, 780 [2005]; *People v Bivens,*88 AD3d 808, 808 [2011]; *People v Bruno,*73 AD3d 941, 941 [2010]; *People v Pooler,*58 AD3d 757, 757 [2009]; *People v Mann,*32 AD3d 865, 866 [2006]; *People v Kucharczyk,*15 AD3d 595, 595 [2005]).

Eng, EJ„ Dickerson, Hall and Lott, JJ, concur.
EXHIBIT 32.1

CERTIFICATION PURSUANT TOTITLE 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzo Biochem,
Inc., and Subsidiaries (the Company)
on Form 10-Q for the period ended October 31, 2007 as filed with the Securities
and Exchange Commission on the date hereof (the Report), I, Elazar
Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. § 1350,
as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

|                         |  |                             
|------------------------ |  | ----------------------------
|Dated: December 10, 2007 |  | By:/s/ Elazar Rabbani, Ph.D.
|                         |  | Elazar Rabbani, Ph.D.       
|                         |  | Chief Executive Officer     

---
Exhibit 10.1


 



AMENDMENT TO THE MANAGEMENT AGREEMENT


This AMENDMENT dated as of the 1st day of June, 2013 to the MANAGEMENT AGREEMENT made as of the 1st day of October, 2005 (the “Management Agreement”), among CERES MANAGED FUTURES LLC (formerly, Citigroup Managed Futures LLC), a Delaware limited liability company (“CMF”), GLOBAL DIVERSIFIED FUTURES FUND L.P. (formerly, Salomon Smith Barney Global Diversified Futures Fund L.P.), a New York limited partnership (the “Partnership”) and Altis Partners (Jersey) Limited, a States of Jersey, Channel Islands corporation (the “Advisor” or “Altis,” all parties together, the “Parties”).  Capitalized terms not defined herein have the meaning ascribed to such terms in the Management Agreement.


W I T N E S S E T H:


WHEREAS, the assets of the Partnership allocated to the Advisor are traded through CMF Altis Partners Master Fund L.P. of which CMF is the general partner and Altis is the Advisor; and


WHEREAS, effective June 1, 2013, the Advisor’s monthly fee for professional management services is being reduced to 1/12 of 1.5% (1.5% per year); and


WHEREAS, the Parties wish to amend the Management Agreement to reflect this change.


NOW, therefore, the Parties agree as follows:


1.  Section 3(a) of the Management Agreement shall be deleted in its entirety and replaced by the following:


“In consideration of and as compensation for all of the services to be rendered by the Advisor to the Partnership under this Agreement, the Partnership shall pay the Advisor (i) an annual incentive fee equal to 20% of New Trading Profits (as such term is defined below) earned by the Advisor for the Partnership and (ii) a monthly fee for professional management services equal to 1/12 of 1.5% (1.5% per year) of the month-end Net Assets of the Partnership allocated to the Advisor.”


2.  The foregoing amendment shall take effect as of the 1st day of June, 2013.


3.  In all other respects the Management Agreement remains unchanged and of full force and effect.


4.  This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same agreement.


[THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK]


 


 













IN WITNESS WHEREOF, this Amendment has been executed for and on behalf of the undersigned as of July 31, 2015.


	 	
CERES MANAGED FUTURES LLC


	 	 
	 	 
	 	
By /s/ Patrick Egan                                  


	 	
Patrick Egan


	 	
President and Director


	 	 
	 	
GLOBAL DIVERSIFIED FUTURES FUND L.P.


	 	 
	 	 
	 	
By: Ceres Managed Futures LLC


	 	
(General Partner)


	 	 
	 	
By /s/ Patrick Egan                                 


	 	
Patrick Egan


	 	
President and Director


	 	 
	 	 
	 	
ALTIS PARTNERS (JERSEY) LIMITED


	 	 
	 	
By /s/ Natasha Reeve-Gray                     


	 	
Name: N. Reeve-Gray

 Title: Principal


	 	 
	 	
By /s/ Stephen Hedgecock                       


	 	
Name: S. Hedgecock

 Title: Principal
EX-10.9



 Exhibit 10.9 

FIRST AMENDMENT 
 TO

 EMPLOYMENT AGREEMENT 

This First Amendment (the “First Amendment”) to that certain Employment Agreement between Seres Therapeutics, Inc., a
Delaware corporation (together with any successor thereto, the “Company”), and David N. Cook, Ph.D. (the “Executive”) dated as of June 13, 2015 (the “Employment Agreement”) is made as of
August 7, 2015 (the “Amendment Date”), by and among the Company and the Executive. 
 WITNESSETH 

WHEREAS, the Company and the Executive desire to amend the terms of the Employment Agreement as set forth herein. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the
Executive hereby agree to the following: 
 1. Amendment to the Employment Agreement. Effective as of the Amendment Date,
Section 4(b)(i) of the Employment Agreement is hereby amended and restated in its entirety to read as follows: 
 (i) an
amount in cash equal to the Annual Base Salary, payable in the form of salary continuation in regular installments over the 12-month period following the date of Executive’s Separation from Service (the “Severance Period”) in
accordance with the Company’s normal payroll practices; 
 2. No Other Amendment. Except as expressly set forth in this First
Amendment, the Employment Agreement shall remain unchanged and shall continue in full force and effect according to its terms. 
 3.
Counterparts. This First Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which together shall constitute one document. 

IN WITNESS WHEREOF, the parties have executed this First Amendment as of the Amendment Date. 

 

			
	 SERES THERAPEUTICS, INC.

		
	 By:
	 	 /s/ Roger J. Pomerantz

	 Name: Roger J. Pomerantz

	 Title: President and Chief Executive Officer

	
	 EXECUTIVE

	
	 /s/ David N. Cook

	 David N. Cook, Ph.D.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM RESORTS
INTERNATIONAL HOTEL, INC.'S CONSOLIDATED FINANCIAL STATEMENTS AND NOTES
THERETO INCLUDED IN THE FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 1996,
EXCEPT AS NOTED BELOW IN FOOTNOTE 3, AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1996
<CASH>                                         $39,072<F1>
<SECURITIES>                                         0
<RECEIVABLES>                                   $8,936
<ALLOWANCES>                                    $3,319
<INVENTORY>                                     $2,064
<CURRENT-ASSETS>                               $53,482
<PP&E>                                        $222,931
<DEPRECIATION>                                 $69,841
<TOTAL-ASSETS>                                $222,489
<CURRENT-LIABILITIES>                          $29,407
<BONDS>                                       $128,292<F2>
<COMMON>                                        $1,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                     $45,080
<TOTAL-LIABILITY-AND-EQUITY>                  $222,489
<SALES>                                              0
<TOTAL-REVENUES>                              $211,136<F3>
<CGS>                                                0
<TOTAL-COSTS>                                 $165,571<F3>
<OTHER-EXPENSES>                                $9,276<F4>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             $13,587
<INCOME-PRETAX>                                   $404
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                               $404
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      $404
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
<FN>
<F1>INCLUDES NON-RESTRICTED CASH EQUIVALENTS OF $25,251 AND RESTRICTED CASH
    EQUIVALENTS OF $750.
<F2>NET OF UNAMORTIZED DISCOUNTS.
<F3>CERTAIN RECLASSIFICATIONS HAVE BEEN MADE TO THE 1996 BALANCES TO CONFORM
    WITH CURRENT YEAR PRESENTATION
<F4>DEPRECIATION EXPENSE.
</FN>
        

</TABLE>
SCWC-10-0000225

IN THE SUPREME COURT OF THE STATE OF HAWAI#I

 

STATE OF HAWAI#I, Petitioner/Plaintiff-Appellee,

vs.

BRYAN K.A. MULLER, Respondent/Defendant-Appellant.

 

CERTIORARI TO THE INTERMEDIATE COURT OF APPEALS

(CAAP-10-0000225; CR. NO. 09-1-0879)

ORDER REJECTING APPLICATION FOR WRIT OF CERTIORARI

(By: Recktenwald, C.J., Nakayama, McKenna, Pollack, and Wilson, JJ.)

Petitioner/Plaintiff-Appellee State of Hawaii’s

application for writ of certiorari filed on March 28, 2014, is

hereby rejected.

DATED: Honolulu, Hawai#i, April 29, 2014.

James M. Anderson

for petitioner

Marcus B. Sierra

for respondent

/s/ Mark E. Recktenwald

/s/ Paula A. Nakayama

/s/ Sabrina S. McKenna

/s/ Richard W. Pollack

/s/ Michael D. Wilson

Electronically Filed

Supreme Court

SCWC-10-0000225

29-APR-2014

07:58 AM
Exhibit 99.6

                        Certification of Chief Financial Officer

                              CERTIFICATION PURSUANT TO
                     SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
                               (18 U.S.C. SECTION 1350)


In connection with the Quarterly Report of 3Si Holdings, Inc.
(the "Company") on Form 10-QSB for the period ended March 31,
2003 as filed with the Securities and Exchange Commission on the
date hereof (the "Report"), the undersigned certifies pursuant
to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as
amended; and

(2) The information contained in the Report fairly presents, in
all material respects, the financial condition and results of
operations of the Company.



Dated: May 13, 2003                    /s/ Frank W. Backes
                                       Frank W. Backes, Chief Technical
                                       Officer, Chief Financial Officer
                                       and Director
Exhibit
32.1




CERTIFICATION
OF CHIEF EXECUTIVE OFFICER


PURSUANT
TO 18 U.S.C. §1350




Pursuant
to 18 U.S.C. §1350 and in connection with the Annual Report on Form 10-K/A, Amendment No. 1 of
Cytomedix, Inc. (the “Company”) for the fiscal year ended December 31, 2008 (the
“Report”), I, Martin P. Rosendale, Chief Executive Officer of the Company,
hereby certify that to the best of my knowledge and belief:




1.
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and




2.
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the Company
      for said period.









/s/
Martin P.
Rosendale


Martin P.
Rosendale


Chief
Executive Officer


Date:  August
10, 2009




A
signed original of this written statement has been provided to Cytomedix, Inc.
and will be retained by Cytomedix, Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA
F OURTH D ISTRICT

ERIK KURT BOE , Appellant,

v.

STATE OF FLORIDA , Appellee

.

No. 4D 17

- 1082

[ June 21, 2018 ]

Appeal from the Circuit Court for the Fifteenth Judicial Circuit, Palm Beach County ; Cheryl Caracuzzo , Judge; L.T. Case No. 50

- 2013

- CF

010169

- BXXX

- MB

.
Carey Haughwout, Public Defender, and Tatjana Ostapoff, Assistant Public Defender, West Palm Beach, for appellant.

Pamela Jo Bondi, Attorney General, Tallahassee, and Mitchell A. Egber, Assistant Attorney General, West Palm Beach, for appellee.

P ER C URIAM

.
Affirmed.

D AMOORGIAN , K LINGENSMITH and K UNTZ , JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
EXHIBIT
      32.2





CERTIFICATION
      PURSUANT TO


18
      U.S.C.
      SECTION 1350,


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002





In
      connection with the Annual Report of Global Diversified Industries, Inc. (the
      "Company") on Form 10-KSB for the period ending April 30, 2005 as filed with
      the
      Securities and Exchange Commission on the date hereof (the "Report"), I, Adam
      Debard, Principal Accounting Officer of the Company, certify to the best of
      my
      knowledge, pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section
      906 of the Sarbanes-Oxley Act of 2002, that:





(1)
      The
      Report fully complies with the requirements of section 13 (a) or 15 (d) of
      the
      Securities and Exchange Act of 1934; and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and result of operations of the Company.





/s/
      Adam
      Debard


----------------------


Adam
      Debard


Principal
      Accounting Officer


August
      15, 2005
**EXHIBIT 32.1**

 

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350

 

The undersigned,Alexander Lidow, the Chief Executive Officer of International RectifierCorporation (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifiesthat, to his knowledge:

 

(i)                                     thequarterly report on Form 10-Q of the Company for the fiscal quarter endedDecember 31, 2005 (the “Report) fully complies with the requirements of section13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(ii)                                  theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company as of, and forthe periods presented in the Report.

 

 

Dated: February 10, 2006

 

 
|   | /s/  Alexander Lidow                  |
|--------|---------------------------------------|
|   | Alexander  Lidow                      |
|   | Director and  Chief Executive Officer |

 

 

A signed original of the written statement required by Section 906 hasbeen provided to International Rectifier Corporation and will be furnished tothe Securities and Exchange Commission or its staff upon request.

 

----
IN THE UNITED STATES DISTRICT COURT FOR THE

SOUTHERN DISTRICT OF ALABAMA

NORTHERN DIVISION

FELICIA BOONE, )

 )

Plaintiff, )

 )

vs. ) CIVIL ACTION 05-0444-CB-D 

 )

PAULINE PADGETT, et al., )

 )

Defendants. )

ORDER

After due and proper consideration of all portions of this file deemed relevant to the issue

raised, and there having been no objections filed, the Report and Recommendation of the Magistrate

Judge made under 28 U.S.C. § 636(b)(1)(B) is ADOPTED as the opinion of this Court. It is

ORDERED that this action be and is hereby DISMISSED without prejudice for failure to prosecute. 

DONE this 30th day of November, 2005.

s/Charles R. Butler, Jr. 

Senior United States District Judge

Case 2:05-cv-00444-CB-D Document 10 Filed 11/30/05 Page 1 of 1